SCHEMBL2471706

SCHEMBL2471706

OCc1onc(-c2ccccc2)c1-c1cn(-c2ccc(C(F)(F)F)cc2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 2/20 0.40
NLRP3 Q96P20 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PTGS1 P23219 2/20 0.38
MAPT P10636 2/20 0.38
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37
EPHX2 P34913 1/20 0.37
MLYCD O95822 1/20 0.37
GABRA5 P31644 1/20 0.36
S1PR1 P21453 1/20 0.36
NR2E1 Q9Y466 1/20 0.34
NOTUM Q6P988 1/20 0.34
TSPO P30536 1/20 0.34
HRH1 P35367 1/20 0.34
OPRD1 P41143 1/20 0.34
P2RY14 Q15391 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2473628 0.91 MCHR1 (0.41) PTGS2MAPTNOTUMTSPOHRH1
SCHEMBL2469106 0.89 PTGS2 (0.47) PTGS2NPC1RAB9ANLRP3PTGS1
SCHEMBL2319847 0.85 ESR1 (0.48) PTGS2NPC1RAB9ANLRP3MEN1
SCHEMBL2468902 0.84 PTGS1 (0.47) PTGS2NPC1RAB9ANLRP3MEN1
SCHEMBL2468940 0.83 PTGS2 (0.41) PTGS2NPC1RAB9ANLRP3MEN1
SCHEMBL2471391 0.80 MCHR1 (0.41) PTGS2NPC1RAB9APTGS1MAPT
SCHEMBL2471438 0.78 MCHR1 (0.39) PTGS2RAB9AGABRA5
SCHEMBL2318319 0.78 ESR1 (0.52) PTGS2NPC1RAB9ANLRP3MEN1
SCHEMBL2317325 0.76 ESR1 (0.48) PTGS2NPC1RAB9ANLRP3KMT2A
SCHEMBL2471762 0.75 PTGS1 (0.47) PTGS2NPC1RAB9APTGS1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1968973-B1 ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-10-05 EP claimed
EP-1968973-A2 ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2008-09-17 EP claimed
US-7414061-B2 Aryl-isoxazol-4-yl-imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-08-19 US claimed
US-20070161654-A1 Aryl-isoxazol-4-yl-imidazole derivatives HOFFMANN-LA ROCHE INC. 2007-07-12 US claimed
WO-2007074078-A2 ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-07-05 WO claimed
EP-1968973-B1 ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-10-05 EP disclosed
EP-1968973-A2 ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2008-09-17 EP disclosed
US-7414061-B2 Aryl-isoxazol-4-yl-imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-08-19 US disclosed
US-20070161654-A1 Aryl-isoxazol-4-yl-imidazole derivatives HOFFMANN-LA ROCHE INC. 2007-07-12 US disclosed
WO-2007074078-A2 ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161654-A1 Aryl-isoxazol-4-yl-imidazole derivatives GABRA5, GABRA4, GABRA1 PTGS2 3762/4885NPC1 1036/4885RAB9A 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.